(Q38853625)

7 September 2017

1 reference

title

Role of interleukin-6 in cancer progression and therapeutic resistance (English)

1 reference

7 September 2017

Neeraj Kumari

1

1 reference

7 September 2017

B S Dwarakanath

series ordinal

2

1 reference

7 September 2017

Asmita Das

series ordinal

3

1 reference

7 September 2017

Anant Narayan Bhatt

series ordinal

4

1 reference

7 September 2017

publication date

3 June 2016

1 reference

7 September 2017

1 reference

7 September 2017

volume

37

1 reference

7 September 2017

issue

9

1 reference

7 September 2017

page(s)

11553-11572

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-016-5098-7

7 September 2017

exact match

0 references

cites work

Inflammation and cancer: IL-6 and STAT3 complete the link.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Autocrine IL-6 signaling: a key event in tumorigenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6--a key regulator of colorectal cancer development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

The role of intratumoral and systemic IL-6 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6: a multifunctional targetable cytokine in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

The role of IL-6 in the radiation response of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Association between adjuvant regional radiotherapy and cognitive function in breast cancer patients treated with conservation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 signaling pathway in targeted therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

NF-kappaB and cancer-identifying targets and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 and its receptors: a highly regulated and dynamic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

The pro- and anti-inflammatory properties of the cytokine interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

IL-6/IL-6 receptor system and its role in physiological and pathological conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Gp130 and the interleukin-6 family of cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Molecular cloning and expression of an IL-6 signal transducer, gp130

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

The soluble interleukin 6 receptor: mechanisms of production and implications in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

The soluble Interleukin 6 receptor: generation and role in inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 and neural stem cells: more than gliogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 and the soluble interleukin-6 receptor induce stem cell factor and Flt-3L expression in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Opposing roles of gp130-mediated STAT-3 and ERK-1/ 2 signaling in liver progenitor cell migration and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Maintenance of pluripotency in human embryonic stem cells is STAT3 independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

IL-6 and NF-IL6 in acute-phase response and viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

p38alpha stabilizes interleukin-6 mRNA via multiple AU-rich elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Postprandial variations of plasma inflammatory markers in abdominally obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Cyclic plasma IL-6 levels during normal menstrual cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6: possible biological roles during exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 at discharge predicts all-cause mortality in patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

The two faces of IL-6 in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

IL‐6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Acute phase reaction and acute phase proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

SOCS3 negatively regulates IL-6 signaling in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Cross-regulation of cytokine signalling: pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Estrogen suppresses hepatocellular carcinoma cells through ERβ-mediated upregulation of the NLRP3 inflammasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Versatile functions for IL-6 in metabolism and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Hypermethylation of tumor suppressor genes in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

The Rb/E2F pathway and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

RB and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

The phosphotidyl inositol 3-kinase/Akt signal pathway is involved in interleukin-6-mediated Mcl-1 upregulation and anti-apoptosis activity in basal cell carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

IL-6 protects against hyperoxia-induced mitochondrial damage via Bcl-2-induced Bak interactions with mitofusins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Bak regulates mitochondrial morphology and pathology during apoptosis by interacting with mitofusins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 activates phosphoinositol-3' kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Role of Stat3 in regulating p53 expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Chronic inflammation and cytokines in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Nuclear factor-kappaB in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Essential role of cooperative NF-κB and Stat3 recruitment to ICAM-1 intronic consensus elements in the regulation of radiation-induced invasion and migration in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Transient elevation of glycolysis confers radio-resistance by facilitating DNA repair in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin 6 enhances glycolysis through expression of the glycolytic enzymes hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

An IL-6 link between obesity and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

NF-kappaB as a primary regulator of the stress response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Oxidative stress activates transcription factor NF-kB-mediated protective signaling in primary rat neuronal cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Activation of interleukin-6 gene expression through the NF-kappa B transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

IL-6 induces NF-kappa B activation in the intestinal epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Oxidative stress, inflammation, and cancer: how are they linked?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin 6 protects H(2)O(2)-induced cardiomyocytes injury through upregulation of prohibitin via STAT3 phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

The basics of epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

DNA damage induces the IL-6/STAT3 signaling pathway, which has anti-senescence and growth-promoting functions in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

DNA damage-mediated induction of a chemoresistant niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 is required for cell cycle arrest and activation of DNA repair enzymes after partial hepatectomy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Chromosomal instability triggered by Rrm2b loss leads to IL-6 secretion and plasmacytic neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Targeting inflammatory pathways for tumor radiosensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Cancer-associated adipocytes promotes breast tumor radioresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

New horizons in tumor microenvironment biology: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Siltuximab (CNTO 328): a promising option for human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Zoledronic acid in breast cancer: latest findings and interpretations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

AG490, a Jak2 inhibitor, suppressed the progression of murine ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

JSI-124 inhibits glioblastoma multiforme cell proliferation through G(2)/M cell cycle arrest and apoptosis augment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Clinical overview of sorafenib in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 as a therapeutic target in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Role of interleukin-6 in the radiation response of liver tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Inhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human B-leukemia cells to apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Stattic: a small-molecule inhibitor of STAT3 activation and dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Eriocalyxin B Inhibits STAT3 Signaling by Covalently Targeting STAT3 and Blocking Phosphorylation and Activation of STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5098-7

IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice

21 January 2018

1 reference

12 December 2020

Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice

1 reference

12 December 2020

Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells.

1 reference

12 December 2020

Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients

1 reference

12 December 2020

IL-6 enriched lung cancer stem-like cell population by inhibition of cell cycle regulators via DNMT1 upregulation

1 reference

12 December 2020

Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

1 reference

12 December 2020

Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway

1 reference

12 December 2020

Inhibition of IL-6 signaling by a p38-dependent pathway occurs in the absence of new protein synthesis

1 reference

12 December 2020

Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma

1 reference

12 December 2020

Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein.

1 reference

12 December 2020

IL-6 enhances the nuclear translocation of DNA cytosine-5-methyltransferase 1 (DNMT1) via phosphorylation of the nuclear localization sequence by the AKT kinase

1 reference

12 December 2020

NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4

1 reference

12 December 2020

NF-κB and STAT3 cooperatively induce IL6 in starved cancer cells

1 reference

12 December 2020

Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies

1 reference

12 December 2020

Adverse events of monoclonal antibodies used for cancer therapy

1 reference

12 December 2020

Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.

1 reference

12 December 2020

Elevation of circulating interleukin 6 after surgery: factors influencing the serum level

1 reference

12 December 2020

IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma

1 reference

12 December 2020

A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma

1 reference

12 December 2020

Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55

1 reference

12 December 2020

Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130

1 reference

12 December 2020

The role of sorafenib in hepatocellular carcinoma.

1 reference

12 December 2020

Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro

1 reference

12 December 2020

Antibody-based therapies in multiple myeloma

1 reference

12 December 2020

Administration of interleukin-6 stimulates multilineage hematopoiesis and accelerates recovery from radiation-induced hematopoietic depression

1 reference

12 December 2020

Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells.

1 reference

12 December 2020

Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma

1 reference

12 December 2020

Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms

1 reference

12 December 2020

Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity

1 reference

12 December 2020

Inhibition of interleukin-6 signaling by galiellalactone

1 reference

12 December 2020

Spontaneous and stimulated interleukin-6 and tumor necrosis factor-alpha production at delivery and three months after birth

1 reference

12 December 2020

Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells.

1 reference

12 December 2020

Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer

1 reference

12 December 2020

Interleukin-6 family of cytokines and gp130

1 reference

12 December 2020

Siltuximab in transplant-ineligible patients with myeloma

1 reference

12 December 2020

IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in ovarian cancer cells

1 reference

12 December 2020

Targeting STAT3 in cancer: how successful are we?

1 reference

12 December 2020

10.1007/S13277-016-5098-7

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1047023130

0 references

1 reference